Warning: This is a preliminary report that has not been peer-reviewed. It should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information.

Gu C, cao X, Wang Z, Hu X, Yao Y, Zhou Y, Liu P, Liu X, Gao G, Hu X, Liang H, Chen Z, Gao L, Peng Y, Jia F, Shan C, Yu L, Liu K, Li N, Guo W, Jiang G, Min J, Zhang J, Yang L, Shi M, Hou T, Li Y, Liang W, Lu G, Yang C, Wang Y, Xia K, Xiao Z, Xue J, Huang X, Chen X, Ma H, Song D, Pan Z, Wang X, Guo H, Liang H, Yuan Z, Guan W, Deng S-J

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which causes coronavirus disease-2019 (COVID-19), interacts with the host cell receptor angiotensin-converting enzyme 2 (hACE2) via its spike 1 protein for infection. After the virus sequence was published, we identified two potent antibodies against SARS-CoV-2 RBD from antibody libraries using a phage-to-yeast (PtY) display ...

Read More

platform in only 10 days. Our lead antibody JMB2002, now in a phase I clinical trial, showed broad-spectrum in vitro blocking activity against hACE2 binding to the RBD of multiple SARS-CoV-2 variants including B.1.351 that was reportedly much more resistant to neutralization by convalescent plasma, vaccine sera and some clinical stage neutralizing antibodies. Furthermore, JMB2002 has demonstrated complete prophylactic and potent therapeutic efficacy in a rhesus macaque disease model. Prophylactic and therapeutic countermeasure intervention of SARS-CoV-2 using JMB2002 would likely slow down the transmission of currently emerged SARS-CoV-2 variants and result in more efficient control of the COVID-19 pandemic.

Date: Feb. 08, 2021

Status: Preliminary Report

View Source: doi: 10.1101/2021.02.07.429299

227061